uBiome Appoints Dr. Joel Kahn, Founder of the Kahn Center for Cardiac Longevity, to its Medical Advisory Board
SAN FRANCISCO (PRWEB) June 26, 2018 -- uBiome, the leader in microbial genomics, announces the addition of Dr. Joel Kahn, a Michigan-based holistic cardiologist and founder of the Kahn Center for Cardiac Longevity, to its Medical Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Kahn will bring to uBiome his extensive experience as a cardiologist focused on the role of diet in heart health, including the connection between heart health and the gut microbiome. The appointment will help uBiome continue its advancement of human microbiome research and further its mission to improve people’s lives.
“Dr. Kahn’s innovative focus on prevention and the role of diet in promoting heart health strongly resonates with uBiome’s mission,” said Dr. Jessica Richman, PhD, co-founder and CEO of uBiome. “We are excited to welcome Dr. Kahn onto our Medical Advisory Board, where his insight will help accelerate our research of the gut microbiome, as it relates to heart health.”
Dr. Joel Kahn is the founder of the Kahn Center for Cardiac Longevity, where he focuses on heart health, cardiac prevention, and recovery through a plant-based diet. A Summa cum Laude graduate of the University of Michigan, Dr. Kahn has been an invasive, interventional, and preventive cardiologist in Detroit since 1980. He holds certificates in Metabolic Cardiology from the University of South Florida and the American Academy of Anti-Aging medicine. Known as the “Holistic Heart Doctor” for his emphasis on diet-based prevention, Dr. Kahn is the author of several bestselling books promoting heart health.
About joining uBiome's Scientific Advisory Board, Dr. Kahn said “In my role as an integrative cardiologist, I have observed that we do not eat for our own nutrition. We eat to feed our microbiome that then decides what we get fed. To not know the health of our gut is to not know our own health. uBiome is a leader in evaluating the status of our bacterial flora in our GI tract to evaluate the root cause of health and disease. I did not foresee it but evaluating stool is the cutting edge in cardiology. Without it we are blind.”
Launched in 2016, SmartGut™ is the world’s first sequencing-based clinical microbiome screening test, providing patients and doctors with actionable insights to improve gut health. The test uses patented precision sequencing technology to identify dozens of microbes associated with specific infections, health risks and gut conditions. SmartGut empowers patients to take steps to understand their gut health and assess actionable information about their gut microbiome with their doctors.
uBiome’s technology platform is based on the largest microbial dataset in the world (over 250,000 samples), covered by six issued patents (and over 100 pending applications), and used in over 20 peer-reviewed publications and presentations. This platform has been used by over 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, University of California, San Francisco, University College London, and University of Sydney.
In addition to Dr. Kahn, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Elaine Hsiao, PhD, Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Jennifer Gardy, PhD, Dr. Jennifer Balkus, Dr. Michael Breus, and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), as well as other accomplished clinicians.
_____
About uBiome:
Founded in 2012, uBiome is the world’s leading microbial genomics company with a mission to advance the science of the microbiome and make useful products to improve human life. uBiome is funded by Y Combinator, Andreessen Horowitz, and 8VC, as well as other leading investors. Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018. Most recently, uBiome was selected as a 2018 Technology Pioneer by the World Economic Forum.
Media Contact:
Lelle Henrichsen
lelle.henrichsen(at)ubiome.com
Lelle Henrichsen, uBiome, http://www.uBiome.com, 1 (415) 842-2466, [email protected]
Share this article